Carcinogenesis, Vol. 24, No. 1, 31-38,
January 2003
© 2003 Oxford University Press
CANCER BIOLOGY |
Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia
The LRF Molecular Pharmacology Specialist Programme, Cancer Research Unit, Newcastle upon Tyne, UK
Defects in the DNA mismatch repair (MMR) pathway have recently been shown to be associated with resistance to several of the cytotoxic drugs used in the treatment of children with acute lymphoblastic leukaemia (ALL). We have assessed the MMR status of a range of leukaemic cell lines using an in vitro repair assay and correlated this with protein expression of the best characterized components of the system. We have also assessed MMR in leukaemic blasts from a limited panel of children with ALL and related this to Ki67 expression as a measure of proliferative capacity. Out of nine leukaemic cell lines tested, five of the seven lymphoid lines showed little or no repair using the in vitro assay and had low MMR protein expression. In three (NALM-6, Reh and MOLT 4) MMR defects have not been previously reported. Immunohistochemistry of clinical samples showed a wide range of expression of MLH1, MSH2 and Ki67 in nine cases studied at presentation, with a highly statistically significant correlation between MLH1 and Ki67 expression (r2 = 0.96, P < 0.0001, Pearson correlation). Western blotting demonstrated high expression of MLH1, PMS2, MSH2 and MSH6 proteins. In vitro analysis of G.T repair using lymphoblast cytosol from the same patients showed a wide range of proficiency, which was markedly reduced in one case studied at relapse. These results suggest that MMR defects are more common in leukaemic cell lines and acute lymphoblastic leukaemias than previously thought.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Yamauchi, M. Ogawa, and T. Ueda Carmustine-Resistant Cancer Cells Are Sensitized to Temozolomide As A Result of Enhanced Mismatch Repair during the Development of Carmustine Resistance Mol. Pharmacol., July 1, 2008; 74(1): 82 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Stoklosa, T. Poplawski, M. Koptyra, M. Nieborowska-Skorska, G. Basak, A. Slupianek, M. Rayevskaya, I. Seferynska, L. Herrera, J. Blasiak, et al. BCR/ABL Inhibits Mismatch Repair to Protect from Apoptosis and Induce Point Mutations Cancer Res., April 15, 2008; 68(8): 2576 - 2580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Matheson, L. A. Hogarth, M. C. Case, J. A.E. Irving, and A. G. Hall DHFR and MSH3 co-amplification in childhood acute lymphoblastic leukaemia, in vitro and in vivo Carcinogenesis, June 1, 2007; 28(6): 1341 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Karran Thiopurines, DNA damage, DNA repair and therapy-related cancer Br. Med. Bull., February 2, 2007; (2007) ldl020v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schmidt, J. A. E. Irving, L. Minto, E. Matheson, L. Nicholson, A. Ploner, W. Parson, A. Kofler, M. Amort, M. Erdel, et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor FASEB J, December 1, 2006; 20(14): 2600 - 2602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A.E. Irving, L. Minto, S. Bailey, and A. G. Hall Loss of Heterozygosity and Somatic Mutations of the Glucocorticoid Receptor Gene Are Rarely Found at Relapse in Pediatric Acute Lymphoblastic Leukemia but May Occur in a Subpopulation Early in the Disease Course Cancer Res., November 1, 2005; 65(21): 9712 - 9718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Velangi, E. C. Matheson, G. J. Morgan, G. H. Jackson, P. R. Taylor, A. G. Hall, and J. A.E. Irving DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma Carcinogenesis, October 1, 2004; 25(10): 1795 - 1803. [Abstract] [Full Text] [PDF]
|
|